Clinical Trials
45 trialsBrodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech SE
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Indiana University
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Alliance for Clinical Trials in Oncology
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Northwestern University
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Duke University
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
National Cancer Institute (NCI)
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Metastatic Cancer
Duke University
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
Alaunos Therapeutics
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Case Comprehensive Cancer Center
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
National Institutes of Health Clinical Center (CC)